As per Seeking Alpha’s quant rating, Teva has been rated Hold, with a score of 2.94 out of 5. It has been rated an A for profitability but has been graded D for valuation. Seeking Alpha analysts have ...
Health insurer Humana has ‌agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly ...
TEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody’s Ratings has upgraded Teva’s corporate credit rating to Baa3 ...
By Mike Scarcella WASHINGTON, Aug 6 (Reuters) - Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from ...
Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after reporting second quarter 2026 results, combining a reported net loss of US$576 million with slightly higher full year revenue guidance ...
Teva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease. The companies plan to provide further details about ...
Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to ...
The pharmaceutical company has a likely blockbuster drug as the flagship of its pipeline.
The big and well-known story surrounding Teva is that the pharmaceutical company focuses on producing generic drugs. Discovering new drugs is a time-consuming, technically complex, and expensive task.
Teva Pharmaceutical Industries Limited is executing a successful turnaround, driven by its "Pivot to Growth" strategy and ...
Details of Teva Pharmaceutical Director’s Share Sale. The Form 4 filing confirms that Tal Zvi Zaks, a Director of Teva ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results